ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1425	National Cancer Institute	Html	en	Ewing Sarcoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of Ewing sarcoma.	ewing sarcoma 0.955451 Localized Ewing Sarcoma 0.516622 standard-risk Ewing sarcoma 0.50921 localized ewing tumors 0.458678 pelvic ewing sarcoma 0.53548 non-metastatic ewing 0.447666 Ewing family tumors 0.476484 Cooperative Ewing Sarcoma 0.57252 Primary Ewing tumor 0.442949 genetically confirmed Ewing 0.443739 recurrent Ewing sarcoma 0.50281 high-risk Ewing sarcoma 0.510965 soft tissue ewing 0.474262 Ewing sarcoma regimen 0.517079 Sarcoma Studies patients 0.436849 sarcoma treatment 0.437736 ewing sarcoma family 0.677203 Ewing sarcoma patients 0.582131 Ewing tumor patients 0.46609 Ewing Sarcoma Study 0.512708 radiation therapy 0.475396 Cutaneous Ewing sarcoma 0.543452 Ewing sarcoma trials 0.520061 extraosseous Ewing sarcoma. 0.438839 et al. 0.575718	extraskeletal Ewing sarcoma 0.55299 tissue Ewing sarcoma 0.517715 sarcoma family tumors 0.500986 Ewing sarcoma molecularly. 0.525686 nonmetastatic Ewing sarcoma 0.582468 secondary Ewing sarcoma 0.532715 PUBMED Abstract 0.436153 extraosseus Ewing tumors 0.450361 extraosseous ewing sarcoma 0.608612 Pediatr Blood Cancer 0.643087 prognosis Ewing family 0.435199 Intergroup Cooperative Ewing 0.452427 advanced Ewing tumors 0.44875 nonmetastatic extraosseous Ewing 0.439621 subcutaneous Ewing sarcoma 0.543232 Ewing sarcoma. 0.468942 primary Ewing sarcoma 0.527784 Abstract 0.588175 Clin Oncol 0.669349 multifocal Ewing sarcoma 0.559473 metastatic Ewing tumors 0.450872 Ewing tumor 0.52176 ewing tumors 0.573464 non metastatic Ewing 0.435213	CLICK HERE
1464	National Cancer Institute	Html	en	Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of malignant mesothelioma.	standard treatment option 0.662037 relatively long survival 0.763744 definitive surgery 0.66758 advanced mesothelioma 0.746687 major symptomatic problems 0.680779 chemotherapy 0.784047 worst prognostic group 0.744191 sarcomatoid mesothelioma 0.794135 bland tumor cells 0.677183 recurrence-free survival 0.667934 clinical trials 0.794592 important prognostic factor. 0.728634 Median survival 0.786141 randomized study 0.677593 patients 0.897231 survival 0.852167 useful immunohistochemical stains 0.67583 CALGB prognostic group 0.748668 progression-free survival rate 0.733148 Cooperative Oncology Group 0.690912 neoadjuvant chemotherapy 0.666321 survival times 0.760237 prognostic value 0.740005 radiation therapy 0.723289	improved survival 0.661891 poorer survival 0.696893 aggressive treatment approaches 0.668925 different treatment modalities 0.670393 aggressive surgical approaches 0.806279 CALGB index 0.684276 mesothelioma diagnoses. 0.716989 Desmoplastic mesothelioma 0.719754 epithelioid mesothelioma 0.727094 adjuvant radiation therapy 0.676072 mesothelioma 0.925011 Advanced Malignant Mesothelioma 0.78476 tissue specimens 0.675675 malignant pleural mesothelioma 0.822532 first-line chemotherapy 0.674756 white blood cell 0.694326 first-line combination chemotherapy 0.748058 recurrent malignant mesothelioma 0.883067 extrapleural pneumonectomy 0.673182 malignant pleural disease 0.743809 large randomized study 0.671727 PDQ summary 0.685413 improved long-term survival 0.756886 prognostic groups 0.660571	CLICK HERE
1534	National Cancer Institute	Html	en	Cartilage (Bovine and Shark) (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of bovine and shark cartilage as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	angiogenesis inhibitor 0.605921 cartilage factor 0.525431 cartilage research 0.52625 cartilage powder 0.542054 cartilage treatment 0.554222 shark cartilage 0.973124 shark cartilage extracts 0.55218 Biol Response Mod 0.51035 cartilage cells 0.557954 new blood vessels 0.487052 tumor angiogenesis 0.46716 dry shark cartilage 0.564932 bovine cartilage 0.627952 patients 0.494925 Natl Cancer Inst 0.505572 vascular endothelial growth 0.488146 novel shark cartilage 0.566963 bovine cartilage extract 0.544409 bovine cartilage extracts 0.534781 shark cartilage extract 0.575893 powdered shark cartilage 0.660454 metastatic renal cell 0.492793 Japanese shark cartilage 0.557325 new endothelial cells 0.468808	shark cartilage products 0.552328 endothelial cells 0.499823 cartilage products 0.616806 Oral shark cartilage 0.568829 angiogenesis inhibitors 0.486536 PUBMED Abstract 0.506075 epiphyseal cartilage 0.523025 cartilage tissue 0.520334 endothelial cell proliferation 0.510942 bovine cartilage preparations 0.556431 human cartilage 0.516475 shark cartilage-derived angiogenesis 0.484691 Catrix treatment 0.468204 shark cartilage product 0.595815 cartilage therapy 0.532177 Abstract 0.525209 endothelial cell 0.516176 renal cell carcinoma 0.554811 phase i/ii trial 0.471371 cartilage-derived collagenase inhibitor 0.469151 tumor 0.475092 shark cartilage inhibitor 0.566866 cancer 0.518101 bovine cartilage therapies 0.544621	CLICK HERE
1727	National Cancer Institute	Html	en	Bone Cancer	A fact sheet about the diagnosis and treatment of cancers that develop in the bones.	benign bone tumors 0.382978 soft tissue 0.317275 osteoid tissue 0.26524 uncommon cancer 0.255981 primary bone cancer 0.577561 cancer cells 0.329155 abnormal bone tissue 0.376855 metastatic cancer 0.262213 bone scan 0.325169 anticancer drugs 0.274172 Cancer Information Service 0.273277 Yes. Cancer 0.261575 tumor causes production 0.259064 healthy bone tissue 0.408981 Yes. Bone cancer 0.36265 Cancer Treatment Research 0.2781 preoperative tumor treatment 0.265675 healthy tissue 0.254742 fibrous tissue 0.263622 clinical trials 0.344137 bone tissue 0.452141 primitive nerve tissue 0.285777 heredity cancer syndromes 0.279206 normal bone tissue 0.410848	Clinical Trials page 0.251984 Ewing Sarcoma Family 0.249697 soft tissue sarcomas 0.285733 incisional biopsy 0.250026 tissue sample 0.258655 blood vessels 0.251489 high-dose external radiation 0.249703 spongy tissue 0.268691 bone marrow 0.344367 cancer centers 0.251332 different types 0.282598 doctor 0.249686 new bone cells 0.361397 bones 0.259461 important treatment option 0.251744 radiation therapy 0.277888 treatment options 0.263715 bone cancer 0.911469 comprehensive cancer information 0.27281 research studies 0.263781 cancerous bone cells 0.36956 bone cancers 0.35903 African American children 0.253491	CLICK HERE
1889	National Cancer Institute	Html	es	Tratamiento del cáncer de colon (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de colon.	siguientes procedimientos 0.92972 pequeña cantidad 0.497446 estadio ii 0.856655 tubo recolector 0.46569 rayos x 0.562684 inferior.ampliar procedimiento 0.480242 enlace drugs approved 0.587222 escáner tep 0.457465 proteína llamada factor 0.458005 National Cancer Institute 0.432943 sustancia llamada gadolinio 0.497309 siguientes riesgos 0.425516 Instituto Nacional 0.460477 PDQ Tratamiento 0.671072 estadio iiia 0.656788 antecedentes familiares 0.459139	estadio iiic 0.63832 cáncer.ampliar sigmoidoscopia 0.46788 estadio iiib 0.647408 estadio iia 0.819513 estadio iic 0.81663 células cancerosas.El bevacizumab 0.49983 Physician Data Query 0.524312 Rectal Cancer 0.499997 cuerpo).ampliar anatomía 0.468805 crecer.El ziv-aflibercept 0.437476 antígeno carcinoembrionario 0.577035 PDQ Cánceres 0.540215 colon forma 0.990115 tejidos sanos circundantes 0.470011 Estadio IVA 0.522216 siguientes pruebas 0.469066	CLICK HERE
1995	National Cancer Institute	Html	es	Tratamiento de la histiocitosis de células de Langerhans (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el tratamiento de la histiocitosis de células de Langerhans infantil.	Immunol Cell Biol 0.40642 langerhans cell 0.852012 lesiones hcl 0.406571 with langerhans 0.417161 langerhans cell histiocytosis 0.986891 multisystem langerhans 0.422209 BRAF V600E-negative Langerhans 0.406114 Langerhans-cell histiocytosis 0.403191 cutaneous langerhans 0.405301 células dendríticas mieloides 0.413633 BRAF Mutation Correlates 0.403764 braf mutation 0.404571 pulmonary langerhans 0.409447 pediatric-onset multisystem langerhans 0.405705 HCL multisistémica 0.436981 pulmonary langerhans cell 0.407403 Grois N 0.403041 cell histiocytosis patients 0.407759 Cell Histiocytosis Study 0.404713 cell histiocytosis harboring 0.404154 mutación v600e 0.406931 dendritic cell differentiation 0.403188 mutación braf v600e 0.411753 histiocytosis lesions reveals 0.403971 Arch Dis Child 0.403576	Emile JF 0.403241 epidermal langerhans cells 0.412171 HCL dérmica 0.409229 BRAF V600E 0.436151 Pediatr Blood Cancer 0.419983 lesiones óseas 0.406722 With High-Risk Langerhans 0.411149 mutaciones braf v600e 0.404471 Multiresistant Langerhans Cell 0.407509 mutación braf 0.412372 braf inhibitor 0.402661 Med Pediatr Oncol 0.402927 Clin Oncol 0.402664 with braf 0.403023 células circulantes 0.409275 adult pulmonary langerhans 0.405666 HCL CD1a-positivas 0.409797 Langerhans'-cell histiocytosis 0.405031 High-Risk Langerhans Cell 0.421727 oncogén braf 0.403238 tratamiento inicial.la hcl 0.405836 with epidermal langerhans 0.411581 childhood langerhans 0.408867 French Langerhans 0.405677	CLICK HERE
15641	National Cancer Institute	Html	en	Research Performance Progress Report (RPPR)	Find more information about the RPPR, which documents recipient accomplishments and compliance with terms of award.	non-competing renewal 0.483928 public access policy 0.676757 NCI program 0.46997 business official 0.461707 grants management specialist 0.511753 Institutional Review Board 0.501375 recipient accomplishments 0.470927 progress reports 0.710572 budget period 0.703772 Performance Progress Report 0.705145 competing project period 0.527715 NCBI 0.472549 NIH staff 0.493692 Type 4s 0.462417 additional information 0.516454 email notification reminders 0.504215 award progress reports 0.597891 PubMed Central ID 0.510154 budget periods 0.468611 Progress Report Additional 0.614182 multiple PIs 0.466396 contact PI 0.464615 award process 0.523874 Management staff review 0.506533 final peer-reviewed journal 0.498525	grants management staff 0.612225 additional information online 0.514579 recipient wishes 0.463817 different schedule 0.465588 Institutional Animal Care 0.498988 annual progress reports 0.586399 progress report 0.93768 scientific progress 0.590143 subsequent budget period 0.638937 final progress report 0.600792 NIH applications 0.499628 eRA Commons 0.829812 full-text papers 0.492864 Non-competing continuation 0.468466 NCI staff 0.465398 Streamlined Noncompeting Award 0.520709 NIH funds 0.496167 NIH Public Access 0.629563 RPPR 0.513098 NIH funding 0.492377 Research Performance Progress 0.694309 Business Technology Transfer 0.507309 incomplete applications 0.461976 Small Business 0.499434	CLICK HERE
16203	National Cancer Institute	Html	en	Ribociclib Improves Progression-Free Survival for Some Women with Metastatic Breast Cancer	A summary of interim results from a phase III trial testing ribociclib plus letrozole (Femara®) as a first-line treatment for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.	Novartis Pharmaceuticals 0.50861 M.D. 0.440705 Postmenopausal women 0.52856 control group 0.563284 second-line therapy 0.517854 proteins—cyclin-dependent kinase 0.519068 CDK4/6 inhibitor 0.52299 Gabriel N. Hortobagyi 0.621331 ribociclib arm 0.512946 median follow-up 0.54408 significantly more neutropenia 0.507111 overall survival 0.538115 Alexandra Zimmer 0.526907 greater share 0.502287 infections 0.43551 Cancer Research 0.512142 first-line treatment 0.673992 tumor cells 0.508198 median progression-free survival 0.787416 clinical trial 0.51962 significant benefit 0.498831 letrozole 0.459254 ribociclib group 0.78322 first-line therapy 0.552793	disease 0.421331 MD Anderson Cancer 0.627314 progression-free survival 0.953616 placebo group 0.714241 careful monitoring 0.503418 patients 0.470449 planned interim analysis 0.594125 adverse events 0.50283 improvement 0.435679 Medicine 0.420889 higher rate 0.49447 NCI’s Center 0.505585 University 0.421021 favor 0.420251 HER2-negative metastatic breast 0.65043 certain types 0.509753 Texas 0.421011 metastatic breast cancer 0.821955 colleagues 0.422295 New England Journal 0.621204 HER2-negative breast cancer 0.726717 Femara® 0.421383 Dr. Zimmer 0.591472	CLICK HERE
16826	National Cancer Institute	Html	en	Early Onset Malignancies Initiative	The Early Onset Malignancies Initiative studies the genomic basis of six cancers that develop at an earlier age, occur in higher rates, and are typically more aggressive in certain minority populations.	community sites 0.48513 control group 0.496806 certain minority populations 0.77365 exome sequencing 0.513318 ethnic populations 0.59564 ethnic groups 0.477288 multiple platforms 0.483426 early detection 0.483135 tumor behavior 0.507221 cutting-edge genomic characterization 0.794697 early age 0.515521 genomic datasets 0.554094 patient populations 0.708455 multiple myeloma 0.479782 critical research 0.469762 rich genomic data 0.741156 cancer types 0.666255 Thorough clinical data 0.657553 extensive data 0.513023 clinical measures 0.479008 molecular targets 0.47719 TCGA 0.415616 tumor progression 0.525349 earlier age 0.508182	higher rates 0.504515 important insights 0.491579 molecular drivers 0.46961 cancer type 0.492461 NCI Genome Characterization 0.808398 early disease 0.497354 clinical updates 0.489197 disease monitoring 0.476658 Genome Characterization Pipeline 0.932301 collaborative initiative 0.505734 NCI genomic characterization 0.824673 EOMI 0.680345 NCI Community Oncology 0.754977 total RNA sequencing 0.668278 underrepresented minorities 0.53639 Cancer Genome Atlas 0.669216 tissue samples 0.659999 Early Onset Malignancies 0.747146 EOMI data 0.528397 treatment response 0.492799 cancer risk 0.496991 genome sequencing 0.549082 Cancer Prevention 0.5334 normal tissue samples 0.654735	CLICK HERE
16859	National Cancer Institute	Html	en	Annual Reporting and Auditing	Reporting helps ensure desired results are achieved throughout the grants lifecycle. Learn more about reporting and auditing requirements for cancer research grants.	audit requirements 0.743431 expenditure data 0.682542 recipient organization 0.553305 Interagency Edison 0.55337 specific grant 0.551262 budget period 0.798124 frequent reporting 0.683485 GPO Stock 0.544524 foreign organizations 0.54552 competing project period 0.68277 federal government 0.548657 management staff review 0.661754 federal support 0.55664 Financial operations 0.549474 for-profit hospitals 0.543055 financial expenditure reports 0.726911 NIH Grants Policy 0.987592 financial status 0.557124 NCI Program 0.553741 cash transaction data 0.661127 For-profit organizations 0.556895 individual award requirements 0.714539 recipient organizations 0.564783 multiple PIs 0.556136 award process 0.560959	grants management staff 0.941167 common reports 0.590648 recipients 0.59377 annual basis 0.550363 annual reports 0.571527 grant award 0.582091 different schedule 0.553636 Contact PI 0.548816 federal awards 0.687649 local government audit 0.75977 progress report 0.54964 subsequent budget period 0.690671 eRA Commons 0.887345 grant activity 0.54536 annual audit 0.999887 official accounting records 0.673267 nonprofit organizations 0.546576 NIH support 0.566195 non-competing continuation 0.568684 Financial reports 0.562828 generally accepted government 0.654669 government auditing standards 0.89142 Grants Policy Statement 0.964206 financial related audit 0.753867	CLICK HERE